What Conceivable Life Sciences does
Conceivable Life Sciences develops AURA, a robotic, AI-guided IVF laboratory system that uses precision robotics, machine vision, and proprietary software to automate the fertilization and embryo-culture workflow that embryologists otherwise perform by hand. The company says its system has produced more than 30 live births and 60+ pregnancies through an IRB-approved clinical study, and it has begun deploying automated labs internationally, including in Mexico City. Conceivable was co-founded in 2022 by Alejandro Chávez-Badiola, Alan Murray, and Joshua Abram, and is headquartered in New York City with additional offices in London, Barcelona, and Guadalajara.
Conceivable Life Sciences is a healthcare tool on Falcoscan. Robotic AI lab that automates IVF embryo creation for fertility clinics. Falcoscan rates Conceivable Life Sciences with an Opportunity score of 86/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Conceivable Life Sciences is founded in 2022, currently at Series_a stage. Pricing: Paid.